



Novel Peptide Drug Conjugate: DBPR376


Institute of Biotechnology and Pharmaceutical Research
National Health Research Institutes




Unmet Medical Need

TNBC market

LHRHR overexpression in ~50% TNBC patients





Ovarian cancer market



LHRHR overexpressed in 86% of prostate cancer, 80% of human endometrial and ovarian cancers, 80% of renal cancer, 50% of breast cancers

IBPR's DESIGN



Product Profile

	LHRH-DM1 Conjugate
Indications	Triple negative breast cancer/ ovarian cancer
<i>in vitro</i> IC₅₀	HCC1806: 11 nM, A2780: 12 nM Detroit551: >20 uM
Plasma stability	Human: 95% after 24 hr. Mouse: 95% after 24 hr
Bio-Distribution	Tumor-targeting vs. DM-1, ~3X more than drug alone
Pharmacokinetics/ Regimen	T _{1/2} > 2 hr (more stable than AN-152) Single or two doses per week for 2-4 weeks @ 1/2 to 1/3 of MTD
<i>in vivo</i> efficacy*	Xenografts: Human TNBC (HCC1806): STR @ indicated regimen Other LHRHR-expressing (Ovarian: A2780) Orthotopic/Patient-derived xenografts: TR @ indicated regimen
Tox-study	100 % survival rate in comparison to Kadcylla No HERG activity